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Structure based drug design has led to the synthesis of novel G-quadruplex binding anti-tumor 
agents. G4-DNA is most commonly found in the promoter region of many oncogenes and in 
telomeres. Stabilization of quadruplex DNA prevents replication and leads to cellular senescence 
or apoptosis. Having a higher affinity for oncogenic over telomeric G4 could give rise to a 
treatment with selectivity for cancerous cells. It is for this reason that many groups are focusing 
on this approach. Anthracenyl-isoxazolyl amides (AIMs) represent a new class of anti-tumor 
agents developed in our laboratories and show potential to stabilize G4. With the aid of NMR 
and CD spectroscopy AIMs have been shown to bind G4. In the NCI 60 cell lines, the AIMs 
exhibit activity comparable to some current chemotherapeutic agents. AIMs provide an 
interesting utility in that they are highly fluorescent, and may be used for confocal imaging. This 
feature coupled with excellent in vivo anti-tumor activity shows the great promise of the AIMs. 
Armed with a strong SAR, current efforts are being put towards increasing activity in confluence 
with optimizing pharmacokinetic properties. Synthesis of molecules containing fused aromatic 
rings becomes increasingly difficult with greater steric encumbrance. Using methods such as the 
Suzuki coupling and Weinreb amidation a late stage diversification point has been exploited. The 
ability to introduce functionality in the later stages of the synthesis has facilitated the possibility 
of generating a more diverse library of molecules. Our current methodology has led to the 
development of a 10-phenyl AIM which exhibits sub-micromolar activity against human 
glioblastoma cells. 
 
